You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Related products

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Filamin A antibody [EP2405Y] - Carboxyterminal end
See all Filamin A products (10) ...

Description

Rabbit monoclonal [EP2405Y] to Filamin A - Carboxyterminal end

Tested applications

WB, IHC-P, ICC, Flow Cytmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

A synthetic peptide corresponding to residues near the C terminal of human Filamin A.

Positive control

COS-1, HeLa, 3T3 and C6 cell lysate and human uterus tissue and Hela cells.

General notes

Produced under U.S. Patent No. 5,675,063.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.01% Sodium Azide
Constituents: 40% Glycerol, 0.05% BSA, Tissue culture supernatant, 0.15M Sodium chloride, 50mM Tris glycine, pH 7.4

Purity

Tissue culture supernatant

Clonality

Monoclonal

Clone number

EP2405Y

Isotype

IgG

  • Flow Cytometry-Filamin A antibody [EP2405Y] - Carboxyterminal end(ab76289)Flow Cytometry-Filamin A antibody [EP2405Y] - Carboxyterminal end(ab76289) image (enlarge)

  • Western blot - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)Western blot - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289) image (enlarge)

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab76289 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • WB: 1/250,000 - 1/500,000.Detects a band of approximately 281 kDa (predicted molecular weight: 281 kDa).

  • ShowHide1 Image

    IHC-P

     IHC-P: 1/100 - 1/250.Per...Read more →

    IHC-P: 1/100 - 1/250.Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.

  • ICC

     ICC: 1/100 - 1/250.

    ICC: 1/100 - 1/250.

  • 1 Image

    Flow Cyt

     Flow Cyt: 1/100

    Flow Cyt: 1/100

Application notes

Is unsuitable for or IP.

Target

Function

Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.

Tissue specificity

Ubiquitous.

Involvement in disease

Defects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period.
Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood.
Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum.
Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects.
Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies.
Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull.
Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion.
Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation.
Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females.
Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets.

Sequence similarities

Belongs to the filamin family.
Contains 1 actin-binding domain.
Contains 2 CH (calponin-homology) domains.
Contains 24 filamin repeats.

Domain

Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.

Post-translational
modifications

Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation.
The N-terminus is blocked.

Cellular localization

Cytoplasm > cell cortex. Cytoplasm > cytoskeleton.

Target information above from: UniProt accessionP21333 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • ABP 280 antibody
  • ABP 280 like protein antibody
  • ABP-280 antibody
  • ABP280A antibody
  • ABPA antibody
  • Actin binding like protein antibody
  • Actin binding protein 280 antibody
  • Actin-binding protein 280 antibody
  • Alpha filamin antibody
  • Alpha-filamin antibody
  • APBX antibody
  • cb967 antibody
  • Dilp2 antibody
  • Endothelial actin binding protein antibody
  • Endothelial actin-binding protein antibody
  • Filamin 1 antibody
  • Filamin A antibody
  • Filamin-1 antibody
  • Filamin-A antibody
  • FLN antibody
  • FLN-A antibody
  • FLN1 antibody
  • FLNA antibody
  • FLNA_HUMAN antibody
  • MNS antibody
  • NHBP antibody
  • Non muscle filamin antibody
  • Non-muscle filamin antibody
  • OPD antibody
  • OPD1 antibody
  • OPD2 antibody
see all

Anti-Filamin A antibody [EP2405Y] - Carboxyterminal end images:

  Flow Cytometry-Filamin A antibody [EP2405Y] - Carboxyterminal end(ab76289)

Flow Cytometry-Filamin A antibody [EP2405Y] - Carboxyterminal end(ab76289)

Overlay histogram showing A431 cells stained with ab76289 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Triton X-100 for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76289 , 1/100 dilutio) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in A431 cells fixed with 4% paraformaldehyde/permeabilized in 0.1% PBS-Triton X-100 used under the same conditions.

  Western blot - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

Western blot - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

All lanes : Anti-Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289) at 1/500000 dilution

Lane 1 : COS-1 cell lysate
Lane 2 : Hela cell lysate
Lane 3 : 3T3 cell lysate
Lane 4 : C6 cell lysate

Lysates/proteins at 10 µg per lane.

Secondary
HRP labelled goat anti-rabbit at 1/1000 dilution

Predicted band size : 281 kDa
Observed band size : 281 kDa

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

Immunohistochemical analysis of paraffin-embedded human uterus using ab76289 at a 1/100 dilution.

  Immunocytochemistry/ Immunofluorescence - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

Immunocytochemistry/ Immunofluorescence - Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

Immunofluorescent staining of HeLa cells using ab76289 at a 1/100 dilution.

References for Anti-Filamin A antibody [EP2405Y] - Carboxyterminal end (ab76289)

This product has been referenced in:

See 1 publication for this product

Publishing research using ab76289? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"